Researchmoz added Most up-to-date research on “PharmaPoint: Microvascular Complications of Diabetes – Italy Drug Forecast and Market Analysis to 2022” to its huge collection of research reports.
The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.
The uptake of drugs receiving additional approval for diabetic retinopathy/DME, such as Eylea, Iluvien and Ozurdex, will further drive sales in the MCD market. A dip in sales in the diabetic neuropathy market will happen from mid-2014 due to the patent expiry of Cymbalta. Another dip in sales in the diabetic neuropathy segment will happen around 2018, when Lyricas patent expires.
Overview of MCD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Italy from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the Italy MCD market.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=186889
Table of Content
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 13
3 Disease Overview 15
3.1 Etiology and Pathophysiology 17
3.1.1 Diabetic Nephropathy 17
3.1.2 Diabetic Retinopathy 19
3.1.3 Diabetic Neuropathy 20
3.2 Prognosis 21
3.3 Quality of Life 22
3.4 Symptoms 23
4 Disease Management 24
4.1 Treatment Overview 24
4.1.1 Diagnosis and Referrals 24
4.1.2 Screening 26
4.1.3 Treatment Guidelines 27
4.2 Italy 34
4.2.1 Diagnosis 34
4.2.2 Clinical Practice 35
For More Information Kindly Contact:
Mr. Nachiket Ghumare,
USA-Canada Toll Free: 866-997-4948
Follow us on LinkedIn @ http://bit.ly/1TBmnVG